Article Dans Une Revue Fundamental & Clinical Pharmacology Année : 2021

Cluster headache: state of the art of pharmacological treatments and therapeutic perspectives

Résumé

Cluster headache (CH) is the most common form of trigeminal autonomic cephalalgia. Current treatments have several limitations, and new drugs are required. This article first briefly reviews present acute and preventive treatments in CH, their mechanism of action and limitations, then describes the state of the art in recent clinical drug trials since 2015, and ends with a critique of trials in the CH field. Research is limited by lack of knowledge of pathophysiology and lack of animal models. In the past 5 years, no brand‐new treatment has emerged, but promising drugs, such as CGRP(R) antibodies, are under study. According to the literature and guidelines, clinicians and researchers should be aware of many limitations in study protocols: concomitant medication, patient sample size, patients’ protocol compliance, and study designs that tend to restrict patient recruitment.
Fichier principal
Vignette du fichier
10.1111_at_fcp.12636.pdf (23.95 Mo) Télécharger le fichier
Origine Fichiers produits par l'(les) auteur(s)

Dates et versions

hal-04799225 , version 1 (24-01-2025)

Identifiants

Citer

Pierre Courault, Genevieve Demarquay, Luc Zimmer, Sophie Lancelot. Cluster headache: state of the art of pharmacological treatments and therapeutic perspectives. Fundamental & Clinical Pharmacology, 2021, Themed series on Neuropharmacology, 35 (3), pp.595-619. ⟨10.1111/fcp.12636⟩. ⟨hal-04799225⟩
16 Consultations
0 Téléchargements

Altmetric

Partager

More